Register
Login:
Share:
Email Facebook Twitter

EXCLUSIVE: Malcy, Columbus & Reabold presentations - Video Webcast Here

EXCLUSIVE: Leo Koot, Exec Chairman, Columbus Energy speaks at London South East's Oil & Gas event
EXCLUSIVE: Stephen Williams, Reabold Resources speaks at London South East's Oil & Gas event


Epistem Holdings Share Price (EHP)



Share Price Information for Epistem Holdings (EHP)


There is currently no data for Epistem Holdings.




London South East Users info for Epistem Holdings




No Recent Trades Information

View more Epistem Holdings trades >>

Directors Deals for Epistem Holdings (EHP)
Trade DateActionNotifierPriceCurrencyAmountHolding
23-Jun-16Placing
Trade Notifier Information for EpiStem Holdings
Ian David Gilham held the position of Interim CEO at EpiStem Holdings at the time of this trade.
 Ian David Gilham
80GBX31,25051750
23-Jun-16Placing
Trade Notifier Information for EpiStem Holdings
Allan Brown held the position of COO at EpiStem Holdings at the time of this trade.
 Allan Brown
80GBX31,25056673
23-Jun-16Placing
Trade Notifier Information for EpiStem Holdings
John Rylands held the position of Finance Director at EpiStem Holdings at the time of this trade.
 John Rylands
80GBX162,500383235
View more Epistem Holdings directors dealings >>


Ctw2014
Posts: 1,620
Opinion:No Opinion
Price:90.00
RNS
7 Jun '16
Any thoughts?
jupiternmars
Posts: 855
Opinion:No Opinion
Price:90.00
Video interview with David Budd
4 May '16
http://tinyurl.com/ho7fhrz

David Budd, chief executive of Epistem Holdings PLC (LON:EHP) says recent tests show its rapid diagnostic system Genedrive is “as accurate as the gold standard”.
Genedrive, which has already launched in India for TB, performed well in EU-funded hepatitis (HCV) study carried out by Institut Pasteur and Hopital Cochin in Paris.
It was 100% accurate in detecting inherited genetic polymorphisms in Hepatitis (HCV) patients compared to the current 'gold-standard' laboratory test, Roche's TaqMan PCR.
“We feel that based on the results that we’ve had today with Institut Pasteur on the qualitative side of detecting HCV that we are in a great position now to go out and find partners that will work with us on commercialising and taking that product to market,” Budd says.
jupiternmars
Posts: 855
Opinion:No Opinion
Price:90.00
Video interview with David Budd
18 Apr '16
http://tinyurl.com/z9crjeq

David Budd, chief executive of Epistem Holdings PLC (LON:EHP) says the news it has reached a major milestone in its development with the full commercial launch of its Genedrive tuberculosis (TB) and antibiotic resistance test, is “hugely significant”.
The company, a specialist in molecular diagnostics and personalised medicine, has teamed up with Xcelris Labs to start selling the product in India.
Next up, Budd says, the company hopes to build up a “menu of tests” over time, now that the company has a “robust technology platform in place”.
Ctw2014
Posts: 1,620
Opinion:No Opinion
Price:95.00
Re excellent
23 Mar '16
Agree. I missed the RNS when it was issued, but a nice $2.9m funding award can't go amiss!
multibag
Posts: 3,116
Opinion:No Opinion
Price:95.00
excellent
21 Mar '16
news folks!
View more share chat for Epistem Holdings (EHP) >>







Share Price, Share Chat, Stock Market news at lse.co.uk
FREE Member Services
- Setup a personalised Watchlist and Virtual Portfolio.
- Gain access to LIVE real-time Regulatory News (RNS).
- View more Trades, Directors' Deals, and Broker Ratings.
Share Price, Share Chat, Stock Market news at lse.co.uk








Datafeed and UK data supplied by NBTrader and Digital Look. While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.